Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
14 analysts have shared their evaluations of Ultragenyx Pharmaceutical (NASDAQ:RARE) over the past three months, showing a mix of bullish and bearish perspectives. The average 12-month price target is $86.79, with a high of $127.00 and a low of $45.00. Recent analyst actions include maintaining, raising, and lowering ratings and price targets.
July 22, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed evaluations of Ultragenyx Pharmaceutical, with an average 12-month price target of $86.79. Recent actions include maintaining, raising, and lowering ratings and price targets.
The mixed analyst ratings and recent adjustments in price targets suggest a cautious optimism towards Ultragenyx Pharmaceutical. The average price target has increased slightly, indicating a positive sentiment. However, the range of price targets from $45.00 to $127.00 shows varying levels of confidence among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100